Last updated: February 20, 2026
Who are the primary suppliers of GIVLAARI (givosiran)?
GIVLAARI (givosiran) is a prescription medication developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP). As of 2023, the supply chain primarily involves Alnylam Pharmaceuticals, which manufactures and distributes GIVLAARI through licensed partners across various regions.
What companies manufacture and distribute GIVLAARI?
| Company |
Role |
Region |
Notes |
| Alnylam Pharmaceuticals |
Manufacturer |
Global |
Developer, primary supplier, and distributor |
| Amneal Pharmaceuticals |
Authorized distributor |
United States |
Licensed for distribution under Alnylam's approval |
| Mylan (now part of Viatris) |
Licensing and distribution rights |
Global (certain regions) |
License agreements for certain territories |
| Other regional distributors |
Licensees and local suppliers |
Europe, Asia, Middle East |
Under licensing agreements or local partnerships |
Manufacturing details
Alnylam uses its proprietary lipid nanoparticle (LNP) technology to produce givosiran. Manufacturing occurs primarily at Alnylam's facilities in the United States and Ireland, which comply with Good Manufacturing Practices (GMP). The company maintains strict quality standards to ensure batch consistency and supply security.
Distribution channels
GIVLAARI distribution hinges on Alnylam's licensing agreements:
- United States: Amneal Pharmaceuticals holds re-seller rights, licensed under Alnylam.
- Europe and other regions: Local pharmaceutical companies hold licensing rights, acting as regional distributors.
These arrangements enable GIVLAARI to reach regional markets efficiently but depend heavily on licensing partner capacity and regulatory approvals.
Regulatory considerations
Manufacturers and distributors must navigate complex regulatory landscapes. GIVLAARI holds approvals from:
- FDA: Approved in the United States since December 2019.
- EMA: Approved in the European Union in 2021.
- Other regions: Under review or pending approval, depending on local regulatory pathways.
Supply continuity hinges on manufacturing compliance with these agencies and timely licensing approvals.
Supply chain risks
- Limited manufacturers: Dependence on Alnylam's production capacity influences supply stability.
- Regional licensing: Supply can be affected by licensing delays or restrictions.
- Raw material sourcing: Lipid nanoparticles require specialized raw materials, which may be subject to global supply constraints.
Summary
Alnylam Pharmaceuticals is the principal manufacturer and global supplier of GIVLAARI. The distribution network is managed through licensing agreements with regional partners like Amneal Pharmaceuticals and local licensees. Manufacturing is concentrated at Alnylam's facilities, with supply stability linked to capacity, licensing efficiency, and raw material availability.
Key Takeaways
- GIVLAARI's supply chain centers on Alnylam Pharmaceuticals as the sole manufacturer.
- Regional distribution relies on licensing agreements with licensed pharmaceutical companies.
- Manufacturing complies with GMP standards, mainly in the United States and Ireland.
- Supply risks include dependence on limited manufacturing capacity and raw material access.
- Regulatory approvals significantly impact manufacturing and distribution scope.
FAQs
1. Who currently manufactures GIVLAARI?
Alnylam Pharmaceuticals owns the manufacturing facilities producing givosiran.
2. Are there multiple suppliers for GIVLAARI?
No, production is concentrated at Alnylam, with regional distribution rights licensed to regional partners.
3. How does licensing affect the availability of GIVLAARI?
Licensing agreements determine regional availability, and delays or restrictions can impact supply.
4. What are the key raw materials used in GIVLAARI manufacturing?
Lipids for nanoparticle formulation, active pharmaceutical ingredients (API), and stabilizers, sourced globally.
5. How has Alnylam ensured supply stability?
Through GMP-compliant manufacturing facilities, scaled capacity, and regional licensing agreements.
References
[1] Alnylam Pharmaceuticals. (2020). GIVLAARI (givosiran) Prescribing Information.
[2] U.S. Food and Drug Administration. (2019). GIVLAARI approved for acute hepatic porphyria.
[3] European Medicines Agency. (2021). GIVLAARI approved in the European Union.
